Shayne C. Gad – författare

Safety pharmacology is the evaluation and study of the pharmacological effects of a potential drug that are unrelated to the desired therapeutic effect. These effects often present a hazard—particularly in individuals with compromised or limited organ system functions.Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition covers safety pharmacology from the regulatory requirements down to the studies that must be done to justify them. Using the author’s more than 30 years of direct experience, the book incorporates tricks and practical insights for making studies work and understanding why they fail. The second edition includes current regulations, including USFDA and those from Europe and Japan. Presenting a clear description of what is needed and why for supporting drug development, the book focuses on updated test methods, interpretation, and science. It covers the core and supplemental batteries of test procedures and how to do them and provides an overview of available facilities and contract organizations for performing studies.

Purposefully designed as a resource for practicing and student toxicologists, Statistics and Experimental Design for Toxicologists and Pharmacologists, Fourth Edition equips you for the regular statistical analysis of experimental data. Starting with the assumption of basic mathematical skills and knowledge, the author supplies a complete and systematic yet practical introduction to the statistical methodologists available for, and used in, the discipline. For every technique presented, a worked example from toxicology is also presented. See what's new in the Fourth Edition:The first practical guide to performing meta analysis allowing for using the power inherent in multiple similar studies Coverage of Bayesian analysis and data analysis in pharmacology and toxicology Almost 200 problems with solutions Discussion of analysis of receptor binding assays, safety pharmacology assays and other standard types conducted in pharmacology A new chapter explaining the basics of Good Laboratory Practices (GLPs) For those with computer skills, this edition has been enhanced with the addition of basic SASWritten specifically for toxicologists and pharmacologists, the author draws on more than 30 years of experience to provide understanding of the philosophical underpinnings for the overall structure of analysis. The book's organization fosters the ordered development of skills and yet still facilitates ease of access to information as needed. This Fourth Edition gives you the tools necessary to perform rigorous and critical analysis of experimental data and the insight to know when to use them.

This practical resource provides toxicologists and scientists with essential information on the regulations that govern their jobs and products. Regulatory Toxicology also covers the scientific and historical underpinnings of those regulations. Each chapter provides a grounding in the historical events that led to the development of original legislation and major subsequent changes in legislation. The major administrative divisions for regulatory agencies and their main missions and responsibilities are also detailed, as are the basic filing units or documents the agencies require of individuals to meet goals. This second edition is updated to reflect new developments in the field.

Choosing the right contract research organization (CRO) can make the difference between getting a product to market quickly and cost-effectively, and wasting valuable time and money. The vast number of available CROs is increasing all the time, and all of them make impressive claims. The Selection and Use of Contract Research Organizations is your essential guide to choosing the best provider.A history of the CRO industry, audit checklists, and overviews of both the pharmaceutical and medical device development processes create a comprehensive overview of how to successfully select and manage a CRO for your project. The book also discusses:Guidance for selection, protocol and contract development, project management and monitoring of work Common pitfalls and problems - how to avoid them, and how to solve them if they do occur How to integrate efforts between groups to achieve the greatest cost effectiveness while maintaining quality and timely production Prototype forms and templates for increasing coordination between multiple working groups A series of appendices covering hundreds of prominent service providers worldwide, including contact information Operative regulations and lawsIn addition to providing fundamental guidance on how to select and manage a CRO in the product development process, this reference also includes a set of eight databases that contain contact information for prominent service providers in North America, Europe, and Japan, and overviews of services they offer. It is a complete resource for professionals in biotechnology, and pharmaceutical and medical device development.

Purposefully designed as a resource for practicing and student toxicologists, Statistics and Experimental Design for Toxicologists and Pharmacologists, Fourth Edition equips you for the regular statistical analysis of experimental data. Starting with the assumption of basic mathematical skills and knowledge, the author supplies a complete and systematic yet practical introduction to the statistical methodologists available for, and used in, the discipline. For every technique presented, a worked example from toxicology is also presented. See what's new in the Fourth Edition:The first practical guide to performing meta analysis allowing for using the power inherent in multiple similar studies Coverage of Bayesian analysis and data analysis in pharmacology and toxicology Almost 200 problems with solutions Discussion of analysis of receptor binding assays, safety pharmacology assays and other standard types conducted in pharmacology A new chapter explaining the basics of Good Laboratory Practices (GLPs) For those with computer skills, this edition has been enhanced with the addition of basic SASWritten specifically for toxicologists and pharmacologists, the author draws on more than 30 years of experience to provide understanding of the philosophical underpinnings for the overall structure of analysis. The book's organization fosters the ordered development of skills and yet still facilitates ease of access to information as needed. This Fourth Edition gives you the tools necessary to perform rigorous and critical analysis of experimental data and the insight to know when to use them.

Toxicology of the Gastrointestinal Tract focuses on the specifics of the mechanisms and adverse effects of xenobiotic agents and pharmaceuticals on the structure and function of the GI tract. The book focuses on a number of specific areas of intestinal research. Beginning with the well-recognized and major functions of nutrient absorption and its role as a protective barrier, the text elaborates on the expanding body of knowledge that relates to the intestines as a major metabolic and immunologic organ involved in the synthesis and degradation of both natural and foreign substances. It includes an overview of the function and dysfunction of the human absorptive process and the effects of microbial flora on these processes, as well as specific classes of toxicants that target the GI tract. The international panel of contributors presents a critical appraisal of the interactions of chemicals and drugs with the gastrointestinal system and the experimental methods and regions of research on which to focus future efforts.Providing a complete and multidisciplinary overview of the gastrointestinal system both in health and as it is involved in the toxicity of exogenous agents, Toxicology of the Gastrointestinal Tract brings together the current and growing knowledge of this critical organ system in a single volume.

Capturing the growth of the global medical device market in recent years, this practical new guide is essential for all who are responsible for ensuring safety in the use and manufacture of medical devices. It has been extensively updated to reflect significant advances, incorporating combination products and helpful case examples of current real-life problems in the field.The Third Edition explores these key current trends: global device marketscontinually advancing technologythe increasing harmonization of device safety regulation worldwide Each aspect of safety evaluation is considered in terms of International Standards Organization (ISO), US Food and Drug Administration (FDA), European Union (EU), and Japanese Ministry of Health and Welfare (MHW) perspectives. In addition, the book reflects the role of the continuing growth of technology in the incorporation of science, particularly in the areas of immunotoxicology and toxicokinetics.

Safety pharmacology is the evaluation and study of the pharmacological effects of a potential drug that are unrelated to the desired therapeutic effect. These effects often present a hazard—particularly in individuals with compromised or limited organ system functions.Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition covers safety pharmacology from the regulatory requirements down to the studies that must be done to justify them. Using the author’s more than 30 years of direct experience, the book incorporates tricks and practical insights for making studies work and understanding why they fail. The second edition includes current regulations, including USFDA and those from Europe and Japan. Presenting a clear description of what is needed and why for supporting drug development, the book focuses on updated test methods, interpretation, and science. It covers the core and supplemental batteries of test procedures and how to do them and provides an overview of available facilities and contract organizations for performing studies.

The inspiration for this text was the 1988 volume by Alder and Zbinden, written before the ICH harmonization process for drug safety evaluation (or its ISO analog for device biocompatibility evaluation) had been initiated or come to force. Since then, much has changed in both the world and practice of medicine and the regulation of drugs. The intent of this volume is to provide similar guidance as to what nonclinical safety assessment tests need to be performed to move a drug into man, through development and to market approved (this intent was subsequently extended to cover the closely related medical device biotechnology, and combination product fields) in a concise, abbreviated manner for all the major world market countries.

Contract Research and Development Organizations: Their Role in Global Product Development has been crafted by these authors to provide a how to guide for all aspects of working with CROs in selecting, working with and ensuring the best possible desirable outcome of having the R&D function, or substantial parts of it, outsourced.

If we will ever achieve Paul Ehrlich’s "magic bullet," that is, a molecule which goes with high selectivity to the therapeutic target site, does what it needs to do, and is subsequently cleared from the body, the practice of safety assessment will have to change. Nonclinical Drug Administration: Formulations, Routes and Regimens for Solving Drug Delivery Problems in Animal Model Systems seeks to address a trio of objectives that, though separate, are linked and central to biomedical science and, ultimately, medicine. Rather seeing these as separate "silos," those working in nonclinical safety assessment will have to view these three in an integrated manner and to regularly and thoughtfully incorporate new information and technology. The trio of objectives this book explores are: first, to present how to deliver more of a drug product systemically to facilitate the regulatory need for evaluating safety and efficacy in animal species (at elevated exposure levels) prior to advancing the drug to human testing; second is to achieve better tolerance to therapeutics administration in test animals and humans which achieves objectives 1 and 3; and third, to explore ways to improve on therapeutic target receptor delivery performance, therefore improving both clinical pharmacodynamics bioavailability and specificity. The book’s ten chapters assemble the basic concepts, principles and hypotheses involved in quantitative receptor and chronological organism interaction dynamics central to the successful development of new therapeutics which depend on systemic administration to achieve desired therapeutic goals and in so doing avoid outcomes which limit, marginalize, or preclude the therapeutic use of so many molecules.

Animal Models in Toxicology is a single-source reference for the use of animal models in toxicology. Chapters cover nine species used in toxicology and experimental biology. With contributions from experts in toxicology, toxicological pathology, and species-specific metabolism, each of these chapters provides an excellent introductory "course" along with guidance to the literature for a more detailed understanding. This edition includes five new chapters. The first of these provides specific and detailed guidance on the humane, efficient, and effective performance of necropsies for laboratory animals. Other new chapters discuss new technologies available for laboratory animal research—imaging technologies, use of telemetry in animal studies, transgenic animal models, and immunology endpoint for assessment. Also provided is an overview of the increasingly complex laws and regulations that govern how laboratory animals are obtained, maintained, and utilized. A helpful appendix provides a quick guide to commercial sources of laboratory animals.

The inspiration for this text was the 1988 volume by Alder and Zbinden, written before the ICH harmonization process for drug safety evaluation (or its ISO analog for device biocompatibility evaluation) had been initiated or come to force. Since then, much has changed in both the world and practice of medicine and the regulation of drugs. The intent of this volume is to provide similar guidance as to what nonclinical safety assessment tests need to be performed to move a drug into man, through development and to market approved (this intent was subsequently extended to cover the closely related medical device biotechnology, and combination product fields) in a concise, abbreviated manner for all the major world market countries.

Contract Research and Development Organizations: Their Role in Global Product Development has been crafted by these authors to provide a how to guide for all aspects of working with CROs in selecting, working with and ensuring the best possible desirable outcome of having the R&D function, or substantial parts of it, outsourced.

This practical book provides toxicologists with essential information on the regulations that govern their jobs and products. Regulatory Toxicology, Third Edition is an up-to-date guide to required safety assessment for the entire range of man-made marketed products. Individual chapters written by experts with extensive experience in the field address requirements not only for human pharmaceuticals and medical devices (for which there are available guidances), but for the full range of man-made products. New in this edition are three chapters addressing Safety Data Sheet Preparation, Regulatory Requirements for GMOs, and Regulatory Requirements for Tobacco and Marijuana. The major administrative divisions for regulatory agencies and their main responsibilities are also detailed, as are the basic filing documents the agencies require. Coverage includes food additives, dietary supplements, cosmetics, over-the-counter drugs, personal care and consumer products, agriculture and GMO products, industrial chemicals, air and drinking water regulations and the special cases of California’s Proposition 65, requirements for safety data sheets, and oversight regulations. Both US and international requirements are clearly presented and referenced. In one volume, those who have regulatory responsibility in companies, lawyers, educators, and those selling these materials in the marketplace can learn about regulatory requirements and how to meet them.

Toxicology has made tremendous strides in the sophistication of the models used to identify and understand the mechanisms of agents that can harm or kill humand and other higher organisms. Non-animals or in vitro models started to gain significant use in the 1960s. As a result of the increased concern over animal welfare, economic factors, and the need for greater sensitivity and understanding of mechanisms, interest in in vitro^n models has risen. This volume demonstrates that there now exists a broad range of in vitro models for use in either identifying or understanding most forms of toxicity.

While the safety assessment (“biocompatibility”) of medical devices has been focused on issues of local tissue tolerance (irritation, sensitization, cytotoxicity) and selected quantal effects (genotoxicity and acute lethality) since first being regulated in the late 1950s, this has changed as devices assumed a much more important role in healthcare and became more complex in both composition and in their design and operation.Add to this that devices now frequently serve as delivery systems for drugs, and that drugs may be combined with devices to improve device performance, and the problems of ensuring patient safety with devices has become significantly more complex.A part of this, requirements for ensuring safety (once based on use of previously acceptable materials – largely polymers and metals) have come to requiring determining which chemical entities are potentially released from a device into patients (and how much is released). Then an appropriate and relevant(yet also conservative) risk assessment must be performed for each identified chemical structure. The challenges inherent in meeting the current requirements are multifold, and this text seeks to identify, understand, and solve all of them.•       Identify and verify the most appropriate available data.•       As in most cases such data is for a different route of exposure, transform it for use in assessing exposure by the route of interest.•       As the duration (and rate) of exposure to moieties released from a device are most frequently different (longer) than what available data speaks to, transformation across tissue is required.•       As innate and adaptive immune responses are a central part of device/patient interaction, assessing potential risks on this basis are required.•       Incorporating assessments for special populations such as neonates.•       Use of (Q)SAR (Quantitative Structure Activity Relationships) modeling in assessments.•       Performance and presentation of integrative assessments covering all potential biologic risks.Appendices will contain summarized available biocompatibility data for commonly used device materials (polymers and metals) and safety assessments on the frequently seen moieties in extractions from devices.

While the safety assessment (“biocompatibility”) of medical devices has been focused on issues of local tissue tolerance (irritation, sensitization, cytotoxicity) and selected quantal effects (genotoxicity and acute lethality) since first being regulated in the late 1950s, this has changed as devices assumed a much more important role in healthcare and became more complex in both composition and in their design and operation.Add to this that devices now frequently serve as delivery systems for drugs, and that drugs may be combined with devices to improve device performance, and the problems of ensuring patient safety with devices has become significantly more complex.A part of this, requirements for ensuring safety (once based on use of previously acceptable materials – largely polymers and metals) have come to requiring determining which chemical entities are potentially released from a device into patients (and how much is released). Then an appropriate and relevant(yet also conservative) risk assessment must be performed for each identified chemical structure. The challenges inherent in meeting the current requirements are multifold, and this text seeks to identify, understand, and solve all of them.•       Identify and verify the most appropriate available data.•       As in most cases such data is for a different route of exposure, transform it for use in assessing exposure by the route of interest.•       As the duration (and rate) of exposure to moieties released from a device are most frequently different (longer) than what available data speaks to, transformation across tissue is required.•       As innate and adaptive immune responses are a central part of device/patient interaction, assessing potential risks on this basis are required.•       Incorporating assessments for special populations such as neonates.•       Use of (Q)SAR (Quantitative Structure Activity Relationships) modeling in assessments.•       Performance and presentation of integrative assessments covering all potential biologic risks.Appendices will contain summarized available biocompatibility data for commonly used device materials (polymers and metals) and safety assessments on the frequently seen moieties in extractions from devices.

This volume provides a complete update of all the materials in prior volumes on the subject (including current directories to testing labs and other support establishments worldwide), while adding substantial new material on the following topics:·        The history of CROs, including snapshots of CROs and a genealogy chart making clear where they came from and where they went.·        Study directors and principal investigators.·        The nuts and bolts of study performance.·        Electronic reporting requirements – SEND and eCTD (required for NDA, BLA, ANDA, and IND submissions).·        Consultants and their roles.·        An expanded examination of common problems and their solutions. This book boastscomplete directories to the global universe of operating labs – where they are, how to contact them, and what they do (including special capabilities). Additionally, checklists for qualifying labs and manufacturing facilities – and for auditing studies and projects at such facilities – are included. It is directed at those in industry (specifically directed at those working for companies using CRO services) but will also be of interest to scientists or administrators working in research organizations themselves. In this case, the contents of this new work are essential to the target reader because the work, regulations, and actors (CROs) have evolved and changed at a rapid pace in the 10 years since the earlier volume that the author published. Likewise, the companies using these services have come to all be almost completely dependent on outsourcing. The earlier texts remain the only source of their kind (paper or electronic) on the field and the only noncommercial guide tothe global industry and this volume provides a complete update.